Doxorubicin-Ebewe

DRUG2 trials

Sponsors

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A., Polska Grupa Badawcza Chloniakow

Conditions

Advanced dedifferentiated liposarcomaHodgkin lymphoma

Phase 2

Brightline-1: A Phase II/III, randomized, open-label, multi-center study of brigimadlin (BI 907828) compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma

CompletedCTIS2024-511361-11-00

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.Advanced dedifferentiated liposarcoma

Start: 2022-03-25End: 2025-11-21Target: 209Updated: 2025-07-04

Phase 3

Efficacy and Tolerability of N-AVD compared to BrECADD in patients with advanced Hodgkin Lymphoma (N-BRAVE)

Not yet recruitingCTIS2026-525263-41-00

Polska Grupa Badawcza ChloniakowHodgkin lymphoma

Target: 370Updated: 2026-05-29